New Combo Products Exempt From Medicaid Rule Applying Price Inflation Rebates To Line Extensions
Executive Summary
CMS final rule narrows definition of new formulations potentially subject to much higher Medicaid rebates and delays effective date of provisions targeting health plan copay accumulator programs.
You may also be interested in...
Copay Assistance Can Be Excluded From Medicaid ‘Best Price’ Without Strings Attached – US Court
Decision is a win for the Pharmaceutical Research and Manufacturers of America in lawsuit against the US Health and Human Services Department.
Copay Assistance Programs Threatened By Medicaid Best Price Rule – PhRMA Lawsuit
The regulatory provisions being challenged are part of a Trump-era “midnight rule” that could be changed by the Biden Administration before implementation, but PhRMA is not taking any chances about the future of copay assistance programs.
CMS’ Brooks-LaSure: Early Action Impacting Pharma Likely To Focus On Legacy Trump Policies
Chiquita Brooks-LaSure’s nomination was approved in a 55-44 vote, with five Republicans joining Democrats in favor. Her confirmation clears the way for other appointments to key positions at the agency, such as the directors of the centers for Medicare and Medicaid.